keyword
MENU ▼
Read by QxMD icon Read
search

Lithium bipolar

keyword
https://www.readbyqxmd.com/read/28214779/lithium-response-in-bipolar-disorder-no-difference-in-gadl1-gene-expression-between-cell-lines-from-excellent-responders-and-non-responders
#1
Jeverson Moreira, Cindie Courtin, Pierre A Geoffroy, Emmanuel Curis, Frank Bellivier, Cynthia Marie-Claire
Previous association studies have shown mixed results between glutamic acid decarboxylase like-1 (GADL1) gene polymorphism and prophylactic lithium response in bipolar disorder (BD) patients. In the present study, GADL1 gene expression was investigated in regard to lithium response, using Alda scale, in lymphoblastoid cells (LCLs) of 36 Caucasian BD patients. No difference in GADL1 expression was observed among LCLs from excellent-responders, non-responders or controls. Furthermore, lithium did not induce significant changes in GADL1 expression levels after 4 or 8 days...
February 14, 2017: Psychiatry Research
https://www.readbyqxmd.com/read/28196994/distressing-cutaneous-lesion-among-bipolar-affective-disorder-patients-on-lithium-therapy-a-retrospective-cross-sectional-study
#2
Syed Ummar, B Lakshmi Dorai, Shree Aarthi Ramanathan
AIM: To assess the incidence of cutaneous lesion in bipolar affective disorder (BPAD) patients on lithium therapy. To evaluate the relationship between duration of lithium therapy, dosage of lithium, serum lithium level, and cutaneous lesions. To assess whether reduction/stoppage of dose of lithium has any change in the course of cutaneous side effects. To look for a relationship between addition of isotretinoin and the course of mood disorder. METHODOLOGY: We retrospectively collected hospital case records of 125 consecutive BPAD patients initiated lithium therapy, assessed with inclusion and exclusion criteria...
October 2016: Indian Journal of Psychiatry
https://www.readbyqxmd.com/read/28194006/genome-wide-association-study-identifies-sestd1-as-a-novel-risk-gene-for-lithium-responsive-bipolar-disorder
#3
J Song, S E Bergen, A Di Florio, R Karlsson, A Charney, D M Ruderfer, E A Stahl, K D Chambert, J L Moran, K Gordon-Smith, L Forty, E K Green, I Jones, L Jones, E M Scolnick, P Sklar, J W Smoller, P Lichtenstein, C Hultman, N Craddock, M Landén
No abstract text is available yet for this article.
February 14, 2017: Molecular Psychiatry
https://www.readbyqxmd.com/read/28188565/poor-quality-of-life-and-functioning-in-bipolar-disorder
#4
Louisa G Sylvia, Rebecca E Montana, Thilo Deckersbach, Michael E Thase, Maurcio Tohen, Noreen Reilly-Harrington, Melvin G McInnis, James H Kocsis, Charles Bowden, Joseph Calabrese, Keming Gao, Terence Ketter, Richard C Shelton, Susan L McElroy, Edward S Friedman, Dustin J Rabideau, Andrew A Nierenberg
BACKGROUND: This study explores the association of demographic and clinical features with quality of life and functioning in individuals with bipolar disorder. METHODS: Adult participants (N = 482) with bipolar I or II disorder were enrolled in a comparative effectiveness study across eleven study sites and completed baseline measures of medical and psychiatric history, current mood, quality of life, and functioning. Participants with at least mildly depressive or manic/hypomanic symptomatic severity were randomized to receive lithium or quetiapine in addition to adjunctive personalized treatment for 6 months...
December 2017: International Journal of Bipolar Disorders
https://www.readbyqxmd.com/read/28185899/lurasidone-versus-treatment-as-usual-for-cognitive-impairment-in-euthymic-patients-with-bipolar-i-disorder-a-randomised-open-label-pilot-study
#5
Lakshmi N Yatham, Sylvia Mackala, Jayasree Basivireddy, Sharon Ahn, Nazlin Walji, Chen Hu, Raymond W Lam, Ivan J Torres
BACKGROUND: Cognitive impairment is present in euthymic patients with bipolar disorder and correlates with impairments in everyday functioning. We aimed to examine the efficacy of lurasidone adjunctive therapy compared with treatment as usual (TAU) in improving cognition. METHODS: For this randomised, open-label, pilot study, we recruited patients aged 19-65 years with euthymic bipolar I disorder from the Mood Disorder Centre in UBC Hospital (Vancouver, Canada)...
February 6, 2017: Lancet Psychiatry
https://www.readbyqxmd.com/read/28168632/long-term-use-of-lurasidone-in-patients-with-bipolar-disorder-safety-and-effectiveness-over-2%C3%A2-years-of-treatment
#6
Andrei Pikalov, Joyce Tsai, Yongcai Mao, Robert Silva, Josephine Cucchiaro, Antony Loebel
BACKGROUND: Bipolar disorder is a chronic illness with a 2-year recurrence rate of approximately 50% among individuals receiving treatment in the community. The aim of this 18-month, open-label, continuation study was to evaluate the long-term safety and effectiveness of lurasidone in patients who initially presented with a major depressive episode associated with bipolar disorder, and who had completed at least 6 months of initial treatment with lurasidone. METHODS: Patients with bipolar I depression were enrolled in one of three 6-week, double-blind, placebo-controlled trials (monotherapy with lurasidone, 1 study; adjunctive therapy with lurasidone; and lithium or valproate, 2 studies)...
December 2017: International Journal of Bipolar Disorders
https://www.readbyqxmd.com/read/28160772/renal-safety-of-lithium-in-hiv-infected-patients-established-on-tenofovir-disoproxil-fumarate-containing-antiretroviral-therapy-analysis-from-a-randomized-placebo-controlled-trial
#7
Eric H Decloedt, Maia Lesosky, Gary Maartens, John A Joska
BACKGROUND: The prevalence of bipolar disorder in HIV-infected patients is higher than the general population. Lithium is the most effective mood stabiliser, while tenofovir disoproxil fumarate (TDF) is frequently used as part of combination antiretroviral therapy (ART). Both TDF and lithium are associated with renal tubular toxicity, which could be additive, or a pharmacokinetic interaction may occur at renal transporters with a decrease in TDF elimination. OBJECTIVE: We report on the change in estimated glomerular filtration rate (eGFR) using the modification of diet in renal disease formula in participants who received ART including TDF and were enrolled in a 24 week randomised trial of lithium versus placebo in patients with HIV-associated neurocognitive impairment...
February 4, 2017: AIDS Research and Therapy
https://www.readbyqxmd.com/read/28160351/comparison-of-treatment-outcome-using-two-definitions-of-rapid-cycling-in-subjects-with-bipolar-ii-disorder
#8
Jay D Amsterdam, Lorenzo Lorenzo-Luaces, Robert J DeRubeis
OBJECTIVES: We examined differences in treatment outcome between Diagnostic and Statistical Manual Fourth Edition (DSM-IV)-defined rapid cycling and average lifetime-defined rapid cycling in subjects with bipolar II disorder. We hypothesized that, compared with the DSM-IV definition, the average lifetime definition of rapid cycling may better identify subjects with a history of more mood lability and a greater likelihood of hypomanic symptom induction during long-term treatment. METHODS: Subjects ≥18 years old with a bipolar II major depressive episode (n=129) were categorized into DSM-IV- and average lifetime-defined rapid cycling and prospectively treated with either venlafaxine or lithium monotherapy for 12 weeks...
February 3, 2017: Bipolar Disorders
https://www.readbyqxmd.com/read/28147361/enantioselective-effect-of-flurbiprofen-on-lithium-disposition-in-rats
#9
Yuichi Uwai, Masashi Matsumoto, Tatsuya Kawasaki, Tomohiro Nabekura
AIMS: Lithium is administered for treating bipolar disorders and is mainly excreted into urine. Nonsteroidal anti-inflammatory drugs inhibit this process. In this study, we examined the enantioselective effect of flurbiprofen on the disposition of lithium in rats. METHODS: Pharmacokinetic experiments with lithium were performed. RESULTS: Until 60 min after the intravenous administration of lithium chloride at 30 mg/kg as a bolus, 17.8% of lithium injected was recovered into the urine...
February 2, 2017: Pharmacology
https://www.readbyqxmd.com/read/28145141/book-review-finding-sanity-john-cade-lithium-and-the-taming-of-bipolar-disorder-de-moore-greg-westmore-ann-allen-and-unwin-sydney
#10
Richard T White
No abstract text is available yet for this article.
February 2017: Australasian Psychiatry: Bulletin of Royal Australian and New Zealand College of Psychiatrists
https://www.readbyqxmd.com/read/28138157/forebrain-specific-ablation-of-phospholipase-c%C3%AE-1-causes-manic-like-behavior
#11
Y R Yang, J H Jung, S-J Kim, K Hamada, A Suzuki, H J Kim, J H Lee, O-B Kwon, Y K Lee, J Kim, E-K Kim, H-J Jang, D-S Kang, J-S Choi, C J Lee, J Marshall, H-Y Koh, C-J Kim, H Seok, S H Kim, J H Choi, Y-B Choi, L Cocco, S H Ryu, J-H Kim, P-G Suh
Manic episodes are one of the major diagnostic symptoms in a spectrum of neuropsychiatric disorders that include schizophrenia, obsessive-compulsive disorder and bipolar disorder (BD). Despite a possible association between BD and the gene encoding phospholipase Cγ1 (PLCG1), its etiological basis remains unclear. Here, we report that mice lacking phospholipase Cγ1 (PLCγ1) in the forebrain (Plcg1(f/f); CaMKII) exhibit hyperactivity, decreased anxiety-like behavior, reduced depressive-related behavior, hyperhedonia, hyperphagia, impaired learning and memory and exaggerated startle responses...
January 31, 2017: Molecular Psychiatry
https://www.readbyqxmd.com/read/28135846/switch-rates-during-acute-treatment-for-bipolar-ii-depression-with-lithium-sertraline-or-the-two-combined-a-randomized-double-blind-comparison
#12
Lori L Altshuler, Catherine A Sugar, Susan L McElroy, Brian Calimlim, Michael Gitlin, Paul E Keck, Ana Aquino-Elias, Brian E Martens, E Grace Fischer, Teri L English, Janine Roach, Trisha Suppes
OBJECTIVE: The authors compared medication-induced mood switch risk (primary outcome), as well as treatment response and side effects (secondary outcomes) with three acute-phase treatments for bipolar II depression. METHOD: In a 16-week, double-blind, multisite comparison study, 142 participants with bipolar II depression were randomly assigned to receive lithium monotherapy (N=49), sertraline monotherapy (N=45), or combination treatment with lithium and sertraline (N=48)...
January 31, 2017: American Journal of Psychiatry
https://www.readbyqxmd.com/read/28135023/nonsteroidal-anti-inflammatory-drugs-nsaids-and-paracetamol-do-not-affect-6-month-mood-stabilizing-treatment-outcome-among-482-patients-with-bipolar-disorder
#13
Ole Köhler-Forsberg, Louisa Sylvia, Michael Thase, Joseph R Calabrese, Thilo Deckersbach, Mauricio Tohen, Charles L Bowden, Melvin McInnis, James H Kocsis, Edward S Friedman, Terence A Ketter, Susan McElroy, Richard C Shelton, Andrew A Nierenberg
BACKGROUND: Many mood disorder patients need analgesics due to increased pain sensitivity. Recent studies have suggested that nonsteroidal anti-inflammatory drugs (NSAIDs) may inhibit antidepressant treatment, which requires replication before clinical recommendations. METHODS: The Clinical and Health Outcomes Initiatives in Comparative Effectiveness for Bipolar Disorder Study randomized participants to 6 months lithium or quetiapine treatment. Use of NSAIDs and paracetamol was assessed throughout the study period and psychopathology measured with the Clinical Global Impression Scale for Bipolar Disorder (CGI-BP) and Bipolar Inventory of Symptoms Scale (BISS)...
January 30, 2017: Depression and Anxiety
https://www.readbyqxmd.com/read/28129310/affective-recurrences-in-bipolar-disorder-after-switching-from-lithium-to-valproate-or-vice-versa-a-series-of-57-cases
#14
Gianluca Rosso, Francesca Solia, Umberto Albert, Giuseppe Maina
No abstract text is available yet for this article.
January 26, 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28117843/neuroprotection-after-a-first-episode-of-mania-a-randomized-controlled-maintenance-trial-comparing-the-effects-of-lithium-and-quetiapine-on-grey-and-white-matter-volume
#15
M Berk, O Dandash, R Daglas, S M Cotton, K Allott, A Fornito, C Suo, P Klauser, B Liberg, L Henry, C Macneil, M Hasty, P McGorry, Cs Pantelis, M Yücel
Lithium and quetiapine are effective treatments for bipolar disorder, but their potential neuroprotective effects in humans remain unclear. A single blinded equivalence randomized controlled maintenance trial was conducted in a prospective cohort of first-episode mania (FEM) patients (n=26) to longitudinally compare the putative protective effects of lithium and quetapine on grey and white matter volume. A healthy control sample was also collected (n=20). Using structural MRI scans, voxel-wise grey and white matter volumes at baseline and changes over time in response to treatment were investigated...
January 24, 2017: Translational Psychiatry
https://www.readbyqxmd.com/read/28117839/the-genetic-overlap-between-mood-disorders-and-cardiometabolic-diseases-a-systematic-review-of-genome-wide-and-candidate-gene-studies
#16
REVIEW
A T Amare, K O Schubert, M Klingler-Hoffmann, S Cohen-Woods, B T Baune
Meta-analyses of genome-wide association studies (meta-GWASs) and candidate gene studies have identified genetic variants associated with cardiovascular diseases, metabolic diseases and mood disorders. Although previous efforts were successful for individual disease conditions (single disease), limited information exists on shared genetic risk between these disorders. This article presents a detailed review and analysis of cardiometabolic diseases risk (CMD-R) genes that are also associated with mood disorders...
January 24, 2017: Translational Psychiatry
https://www.readbyqxmd.com/read/28114089/-non-conventional-pharmacological-agents-for-the-treatment-of-bipolar-disorder-%C3%AE-systematic-review-of-the-evidence
#17
K N Fountoulakis, D Balaris, V Nikolaou, J Νimatoudis
Bipolar disorder (BD) has a complex and variable clinical picture which is characterized by many different phacets and phases and as a result its therapeutical options are also complex and often unsatisfactory. Typically the so-called "mood stabilizers" are used in the treatment of BD and in this class lithium and specific antiepileptics are included. The present study aimed to systematically review the literature concerning the presence of randomized double blind clinical trials of 'non conventional' pharmaceutical treatment options...
October 2016: Psychiatrikē, Psychiatriki
https://www.readbyqxmd.com/read/28109561/lithium-reverses-behavioral-and-axonal-transport-related-changes-associated-with-ank3-bipolar-disorder-gene-disruption
#18
Michael G Gottschalk, Melanie P Leussis, Tillmann Ruland, Klaudio Gjeluci, Tracey L Petryshen, Sabine Bahn
Ankyrin 3 (ANK3) has been implicated as a genetic risk factor for bipolar disorder (BD), however the resulting pathophysiological and treatment implications remain elusive. In a preclinical systems biological approach, we aimed to characterize the behavioral and proteomic effects of Ank3 haploinsufficiency and chronic mood-stabilizer treatment in mice. Psychiatric-related behavior was evaluated with the novelty-suppressed feeding (NSF) paradigm, elevated plus maze (EPM) and a passive avoidance task (PAT). Tandem mass spectrometry (MS(E)) was employed for hippocampal proteome profiling...
January 18, 2017: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28108944/the-seroprevalence-of-antithyroid-peroxidase-antibodies-in-bipolar-families-and-bipolar-twins-results-from-two-longitudinal-studies
#19
G Snijders, L de Witte, E Mesman, S Kemner, R Vonk, R Brouwer, W A Nolen, H A Drexhage, M H J Hillegers
BACKGROUND: Previous studies of our group among bipolar offspring and bipolar twins showed significant higher prevalence's and levels of antithyroid peroxidase antibodies (TPO-Abs) in offspring and co-twins (without a mood disorder) compared to controls, suggesting that TPO-Abs might be considered as vulnerability factor (trait marker) for BD development. OBJECTIVES: Here we elucidate, in the same cohorts, but now after 12- and 6-year follow-up, whether TPO-abs should be considered as a 'trait' marker for BD...
December 2017: International Journal of Bipolar Disorders
https://www.readbyqxmd.com/read/28106616/lymphocyte-phospho-ser-9-gsk-3%C3%AE-total-gsk-3%C3%AE-protein-levels-ratio-is-not-affected-by-chronic-lithium-or-valproate-treatment-in-euthymic-patients-with-bipolar-disorder
#20
Abed N Azab, Ella Vainer, Galila Agam, Yuly Bersudsky
BACKGROUND: Glycogen synthase kinase-3 (GSK-3) inhibition by lithium has been well established in vitro, but proof that this biochemical effect mediates lithium's beneficial action in patients with bipolar disorder is lacking. We studied whether lymphocyte GSK-3β activity measured indirectly in lithium- or valproate (VPA)-treated euthymic patients with bipolar disorder is different from controls. METHODS: Lymphocyte total and Ser-9-phospho-GSK-3β (inactive) levels were measured by Western blotting...
January 19, 2017: Journal of Clinical Psychopharmacology
keyword
keyword
69613
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"